Lord Jonathan T. MD - 08 Jun 2023 Form 4 Insider Report for BIOLASE, INC (BIOLQ)

Reporting relationship: Director
Issuer ticker: BIOLQ
Reported as of: 08 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2023, 08:57:59 UTC
Prior SEC filing: 08 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael C. Carroll, attorney-in-fact for Jonathan T. Lord

Key filing fact

Lord Jonathan T. MD filed Form 4 for BIOLASE, INC (BIOLQ) on 12 Jun 2023.

Key facts

This page summarizes Lord Jonathan T. MD's Form 4 filing for BIOLASE, INC (BIOLQ).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2023, 08:57.

Change

Previous filing in this sequence was filed on 08 Dec 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIOL transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +721,154
Change %: +1228%
Price: $0.000000
Shares after: 779,901
Date: 08 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 721,154
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.

Footnote F2

The restricted stock unit award fully vests and is immediately exercisable upon the eleventh month anniversary of the date of grant.